Results 21 to 30 of about 282,663 (297)

Prevalence and diagnostic performance of iron deficiency in polycythemia

Hematology, 2023
Introduction Several observations have shown that patients with polycythemia have iron deficiency. Our objectives were to report the prevalence of iron deficiency and to evaluate the diagnostic performance of serum ferritin in polycythemia vera.Patients ...
Rova Malala Fandresena Randrianarisoa, Herveat Ramanandafy, Alexandre Mania, Hélène Monjanel, Sébastien Trouillier   +4 more
doaj   +1 more source

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b

Leukemia, 2022
TO THE EDITOR: Interferon alfa not only restores normal blood cell counts in patients with polycythemia vera (PV) but can diminish the mutant JAK2 V617F allele burden [1 – 3].
J. Kiladjian, C. Klade, P. Georgiev, D. Krochmalczyk, L. Gercheva‐Kyuchukova, M. Egyed, P. Dulíček, Á. Illés, H. Pylypenko, L. Sivcheva, J. Mayer, V. Yablokova, K. Krejcy, V. Empson, H. Hasselbalch, R. Kralovics, H. Gisslinger, Jean-Jacques Pencho Dorota Liana Miklos Petr Arpad Halyna Lylia Kiladjian Georgiev Krochmalczyk Gercheva-Kyuchukov, J. Kiladjian   +18 more
semanticscholar   +1 more source

Polycythemia vera is a medical condition characterized by raised hematocrit. Owing to increased viscosity, the blood flow in the vessels become sluggish leading to the clinical features of polycythemia such as headache, blurring of vision, red skin, dizzi

Journal of Bahria University Medical and Dental College, 2021
Polycythemia vera is a medical condition characterized by raised hematocrit. Owing to increased viscosity, the blood flow in the vessels become sluggish leading to the clinical features of polycythemia such as headache, blurring of vision, red skin ...
Nabeela Iqbal, Syed Khalid Shah, Shamima Haneef   +2 more
doaj   +1 more source

Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera

Blood Cancer Journal, 2022
We investigated the neutrophil-to-lymphocyte ratio (NLR) as a predictor of thrombosis in polycythemia vera (PV). After a median follow-up of 2.51 years, of 1508 PV patients enrolled in the ECLAP study, 82 and 84 developed arterial and venous thrombosis ...
A. Carobbio, A. Vannucchi, V. De Stefano, A. Masciulli, P. Guglielmelli, G. G. Loscocco, Francesco Ramundo, E. Rossi, Y. Kanthi, A. Tefferi, T. Barbui   +10 more
semanticscholar   +1 more source

Precision Dosing in Presence of Multiobjective Therapies by Integrating Reinforcement Learning and PK-PD Models: Application to Givinostat Treatment of Polycythemia Vera. [PDF]

CPT Pharmacometrics Syst Pharmacol
ABSTRACT Precision dosing aims to optimize and customize pharmacological treatment at the individual level. The integration of pharmacometric models with Reinforcement Learning (RL) algorithms is currently under investigation to support the personalization of adaptive dosing therapies.
De Carlo A, Tosca EM, Magni P.
europepmc   +2 more sources

Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea

Cancer, 2022
Ruxolitinib is approved for patients with polycythemia vera (PV) who are resistant/intolerant to hydroxyurea, but its impact on preventing thrombosis or disease‐progression is unknown.
A. Álvarez-Larrán, M. Garrote, F. Ferrer-Marín, M. Pérez-Encinas, M. Mata-Vázquez, B. Bellosillo, E. Arellano-Rodrigo, Montse Gómez, R. García, V. García‐Gutiérrez, M. Gasior, B. Cuevas, A. Angona, M. Gómez-Casares, C. Martínez, E. Magro, R. Ayala, Rafael del Orbe-Barreto, R. Pérez-López, M. Fox, J. Raya, Lucía Guerrero, C. García-Hernández, G. Caballero, Ilda Murillo, B. Xicoy, M. Ramírez, G. Carreño-Tarragona, J. Hernández-Boluda, Arturo Pereira   +29 more
semanticscholar   +1 more source

Genetic Background of Polycythemia Vera

Genes, 2022
Polycythemia vera belongs to myeloproliferative neoplasms, essentially by affecting the erythroblastic lineage. JAK2 alterations have emerged as major driver mutations triggering PV-phenotype with the V617F mutation detected in nearly 98% of cases.
Mathilde Regimbeau, Romain Mary, F. Hermetet, F. Girodon   +3 more
semanticscholar   +1 more source

Polisitemi Veralı Hastalarda Dinamik Thiol/Disulfit Dengesi ve İskemi Modifiye Albumin Düzeyleri

Düzce Tıp Fakültesi Dergisi, 2021
Aim: Polycythemia vera is a chronic myeloproliferative disease characterized by increased red cell mass and JAK2 mutation positivity. Transformation to myelofibrosis and acute leukemia is possible in patients with polycythemia vera.
Özcan Erel, Hakan Basir, Mustafa Ilgan, Eyüp Naci Tiftik, Mahmut Bakır Koyuncu, Mehmet Ali Uçar, Aydan Akdeniz, Anıl Tombak, Salim Neşelioğlu   +8 more
doaj   +1 more source

Polycythemia vera: historical oversights, diagnostic details, and therapeutic views

Leukemia, 2021
Polycythemia vera (PV) is a relatively indolent myeloid neoplasm with median survival that exceeds 35 years in young patients, but its natural history might be interrupted by thrombotic, fibrotic, or leukemic events, with respective 20-year rates of 26%,
A. Tefferi, A. Vannucchi, T. Barbui
semanticscholar   +1 more source

Polycythemia vera presenting with pulmonary embolism and splenic infarction: a case report

Journal of International Medical Research, 2022
Pulmonary embolism and splenic infarction are rare in patients with polycythemia vera. We herein describe a man in his early 60s whose main symptoms were chest tightness, cough, and sputum expectoration.
Ping Huang, Yuhong Li
doaj   +1 more source